NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
REDAtezolizumab 840mg & 1200mg Tecentriq®
(Intravenous infusion) 		Malignant disease and immunosuppression, Other antineoplastic drugs, 08.01.05
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Atezolizumab  Atezolizumab [Specialist Drug] Malignant Disease, Antineoplastic Drugs, Monoclonal Antibodies
Antibody Responsive Malignancy
Selecting a button in the local column will search the local formulary again for the word on the button. Where the button is in outline no local match at drug name level was found.
Links found
NICE TA1047: Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (TERMINATED APPRAISAL)
NICE TA1071: Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer
NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
NICE TA584 Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
NICE TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma
NICE TA705: Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer
NICE TA739: Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable
NICE TA823: Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer